Average Target Price for Japan Tobacco Increases 7.54%

Market by 2FIRSTS.ai

Dec.18.2023

Average Target Price for Japan Tobacco Increases 7.54%

The average target price for Japan Tobacco has been revised to $23.43, a 7.54% increase since August 1.

According to investment platform Fintel, recent reports have shown that the average one-year target price for Japan Tobacco (OTC:JAPAF) has been revised to $23.43 per share, representing a 7.54% increase from the valuation of $21.78 per share on August 1, 2023.

The target price is the average forecast provided by numerous analysts. The latest target price range is from a low of $15.69 per share to a high of $28.92 per share. This average target price represents a decrease of 7.33% from the recent closing price of $25.28 per share.

Furthermore, 334 funds or institutions were reported to hold shares of Japan Tobacco, a decrease of 5 or 1.47% from the previous quarter. The average holding ratio of all funds investing in Japan Tobacco was 0.37%, a decrease of 0.21% compared to the previous quarter. The total number of shares held by institutions increased by 0.95% in the past three months to reach 108,634K shares.

References:

[1] Japan Tobacco (JAPAF) Price Target Increased by 7.54% to 23.43

Also Read:

[1] Japan Tobacco Inc. Stock Price Declines by 0.9% on December 5th

[2] Japan Tobacco Inc's Stocks Soar by 4.1% in Trading

[3] Japan Tobacco Inc.: Stock Price Dropped 0.9% in Tuesday's Trading

#Traditional tobacco #Asia #Market #Japan

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Argentine province of Santa Fe passes bill expanding smoking regulations to include e-cigarettes and heated tobacco products

The Santa Fe Provincial Chamber of Deputies has passed a bill amending the 2005 Provincial Anti-Smoking Law (No. 12,432) to include e-cigarettes, vaping devices, and heated tobacco products. Lawmaker Sonia Martorano, who authored the initiative, said the reform aims to strengthen prevention policies amid growing youth use, stressing that “even without nicotine, these devices are toxic.”

Nov.05 by 2FIRSTS.ai

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

South Korea Again Delays Tobacco Business Act Amendment on Synthetic Nicotine

South Korea’s amendment to the Tobacco Business Act, which would classify synthetic nicotine vapes and vape liquids as “tobacco” for regulatory and taxation purposes, has been delayed once again. Despite the government stressing its urgency due to youth access and risks of illicit drug mixing, both ruling and opposition parties at the Legislation and Judiciary Committee meeting agreed that the bill requires further discussion.

Nov.13 by 2FIRSTS.ai

The Pinnacle of Craftsmanship: Great Wall Cigars' Exclusive 2025 Releases

Great Wall Cigars presents its latest premium collection, blending Chinese heritage with global craftsmanship. From the Cameroon-tobacco GX Lion’s Glory Toro to the zodiac-themed Year of the Horse and Year of the Snake editions, each cigar embodies artistry and rarity. Alongside the refined Spectacular No.2 and No.3 Extra Finos, the lineup marks Great Wall’s rise as a symbol of Chinese cigar excellence on the world stage.